Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 12/20 | 0.76 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.68 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.68 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.68 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.68 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | PDE5A | O76074 | 1/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | PRKCA | P17252 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 1/20 | 0.56 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31187090 | 0.90 | ESR1 (0.61) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| SCHEMBL28485097 | 0.90 | ESR1 (0.71) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| SCHEMBL31517131 | 0.87 | MAPT (0.65) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| SCHEMBL17387053 | 0.86 | ESR1 (1.00) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| SCHEMBL3965403 | 0.85 | CACNA1H (0.72) | ESR1ESR2AKR1B1CACNA1GCACNA1H | |
| SCHEMBL13893460 | 0.83 | ESR1 (0.82) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| SCHEMBL5313882 | 0.83 | ESR1 (1.00) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| SCHEMBL1931876 | 0.83 | ESR1 (1.00) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| Sophoraflavanone B SCHEMBL14304885 | 0.81 | ESR1 (1.00) | ESR1ESR2ABCG2AKR1B10AKR1B1 | |
| Sophoraflavanone B SCHEMBL29396586 | 0.81 | ESR1 (1.00) | ESR1ESR2ABCG2AKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024087261-A1 | METHOD FOR EXTRACTING, SEPARATING, AND PURIFYING 8-PRENYLNARINGENIN FROM HOPS | 长沙市惠瑞生物科技有限公司 | 2024-05-02 | — | — | WO | claimed |
| CN-115650942-A | Method for extracting, separating and purifying 8-isopentenyl naringenin from hops | 长沙市惠瑞生物科技有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-115364144-A | Yuqing lobular Kuding tea extract and preparation method and application thereof | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 2022-11-22 | — | — | CN | claimed |
| CN-114146083-A | Sophora flower extract and active component and application thereof in preparation of product for treating glycolipid metabolic syndrome | 天津科技大学 | 2022-03-08 | — | — | CN | claimed |
| US-10512667-B2 | Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-12-24 | — | — | US | claimed |
| US-20180369321-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO ADRENOCORTICAL ACTIVITY AND/OR EXCESSIVE STEROID PRODUCTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-12-27 | — | — | US | claimed |
| WO-2024212685-A1 | USE OF INTEGRIN Α5Β1 AS TARGET IN SCREENING OF DRUGS FOR PREVENTING AND/OR TREATING BONE LOSS | 香港理工大学 | 2024-10-17 | — | — | WO | disclosed |
| EP-4393488-A1 | COMPOSITION COMPRISING AT LEAST ONE NATURAL OR SYNTHETIC N-ALKYLAMIDE AS ACTIVE SUBSTANCE AND METHOD FOR MANUFACTURING SAME | Eleonor (BE) | 2024-07-03 | — | — | EP | disclosed |
| US-20240207205-A1 | COMPOSITION COMPRISING AT LEAST ONE NATURAL OR SYNTHETIC N-ALKYLAMIDE AS ACTIVE SUBSTANCE AND ITS MANUFACTURING PROCESS | ELEONOR SPRL (BE) | 2024-06-27 | — | — | US | disclosed |
| WO-2024087261-A1 | METHOD FOR EXTRACTING, SEPARATING, AND PURIFYING 8-PRENYLNARINGENIN FROM HOPS | 长沙市惠瑞生物科技有限公司 | 2024-05-02 | — | — | WO | disclosed |
| US-20230381135-A1 | COMPOSITION COMPRISING AT LEAST ONE LABDANE DITERPENE AND METHOD FOR MANUFACTURING SAME | ELEONOR (BE) | 2023-11-30 | — | — | US | disclosed |
| EP-4228604-A1 | COMPOSITION COMPRISING AT LEAST ONE LABDANE DITERPENE AND METHOD FOR MANUFACTURING SAME | Tilman (BE) | 2023-08-23 | — | — | EP | disclosed |
| EP-4135666-A1 | COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERINE ALKALOID AND METHOD FOR MANUFACTURING SAME | Eleonor (BE) | 2023-02-22 | — | — | EP | disclosed |
| CN-101871924-A | Method for synchronous detection of xanthohumol, isoxanthohumol and 8-isopentenylnaringenin in lupulus | UNIV ZHEJIANG | 2010-10-27 | — | — | CN | disclosed |
| CN-101871924-A | Method for synchronous detection of xanthohumol, isoxanthohumol and 8-isopentenylnaringenin in lupulus | UNIV ZHEJIANG | 2010-10-27 | — | — | CN | disclosed |
| WO-2010039679-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2010-04-08 | — | — | WO | disclosed |
| WO-2008003774-A1 | METHOD FOR PRODUCING ENANTIOPURE FLAVANONES | Technische Universität Dresden (DE) | 2008-01-10 | — | — | WO | disclosed |
| US-20050019438-A1 | Hop extracts and use thereof in the production of a medicament having estrogenic properties | BOURGES-SEVENIER CEDRIC (FR) | 2005-01-27 | — | — | US | disclosed |
| EP-1381379-A1 | HOP EXTRACTS AND USE THEREOF IN THE PRODUCTION OF A MEDICAMENT HAVING ESTROGENIC PROPERTIES | BERKEM (FR) | 2004-01-21 | — | — | EP | disclosed |
| WO-2002085393-A1 | HOP EXTRACTS AND USE THEREOF IN THE PRODUCTION OF A MEDICAMENT HAVING ESTROGENIC PROPERTIES | BERKEM (FR) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207205-A1 | COMPOSITION COMPRISING AT LEAST ONE NATURAL OR SYNTHETIC N-ALKYLAMIDE AS ACTIVE SUBSTANCE AND ITS MANUFACTURING PROCESS | NPPA, PIGS, IAPP | ESR1 4706/4885ESR2 4093/4885ABCG2 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.